BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: deSouza NM, Liu Y, Chiti A, Oprea-lager D, Gebhart G, Van Beers BE, Herrmann K, Lecouvet FE. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. European Journal of Cancer 2018;91:153-63. [DOI: 10.1016/j.ejca.2017.12.012] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Vigna-taglianti R, Boriano A, Merlotti AM, Martini S, Martini S, Luca G, Solla S, Lavinia S, Olivero F, Bergesio F, De Maggi A, Reali A, Grazioso Russi E. Long Term Results of Elective Nodal Salvage Radiotherapy in Oligometastatic Prostate Cancer : A Mono-Institutional Series. ann urol oncol 2022. [DOI: 10.32948/auo.2022.09.30] [Reference Citation Analysis]
2 Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D'Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R; OMEC-working group (Supplementary File 1). Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Eur J Surg Oncol 2022:S0748-7983(22)00682-5. [PMID: 36184420 DOI: 10.1016/j.ejso.2022.09.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Xu D, Yu F, Guo T, Zhou Y, Zhang J, Li Y, Jiang S, Mao J, Yang X, Chu L, Chu X, Wang S, Ni J, Zhu Z. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. BJR 2022;95. [DOI: 10.1259/bjr.20220035] [Reference Citation Analysis]
4 Aristei C, Bölükbaşı Y, Kaidar-Person O, Pfeffer R, Arenas M, Boersma LJ, Ciabattoni A, Coles CE, Franco P, Krengli M, Leonardi MC, Marazzi F, Masiello V, Meattini I, Montero A, Offersen B, Trigo ML, Bourgier C, Genovesi D, Kouloulias V, Morganti AG, Meduri B, Pasinetti N, Pedretti S, Perrucci E, Rivera S, Tombolini V, Vidali C, Valentini V, Poortmans P. Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting. Crit Rev Oncol Hematol 2022;:103774. [PMID: 35917884 DOI: 10.1016/j.critrevonc.2022.103774] [Reference Citation Analysis]
5 De Rose F, Meduri B, Carmen De Santis M, Ferro A, Marino L, Ray Colciago R, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delaloge S, Cortes J, Curigliano G. Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102434] [Reference Citation Analysis]
6 Ma R, Zhao Q, Zhao R, Li J, Wang Y. Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer. Nuclear Medicine Communications 2022;Publish Ahead of Print. [DOI: 10.1097/mnm.0000000000001599] [Reference Citation Analysis]
7 Kahán Z, Szántó I, Dudás R, Kapitány Z, Molnár M, Koncz Z, Mailáth M. Breast Cancer Survivorship Programme: Follow-Up, Rehabilitation, Psychosocial Oncology Care. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res 2022;28:1610391. [PMID: 35721327 DOI: 10.3389/pore.2022.1610391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 van der Velden J, Willmann J, Spałek M, Oldenburger E, Brown S, Kazmierska J, Andratschke N, Menten J, van der Linden Y, Hoskin P. ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol 2022:S0167-8140(22)04130-5. [PMID: 35661676 DOI: 10.1016/j.radonc.2022.05.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Vietti Violi N, Hajri R, Haefliger L, Nicod-Lalonde M, Villard N, Dromain C. Imaging of Oligometastatic Disease. Cancers (Basel) 2022;14:1427. [PMID: 35326586 DOI: 10.3390/cancers14061427] [Reference Citation Analysis]
10 Konovalenko V, Drobotun O, Ternovyy N, Konovalenko S, Garashchenko O. Monitoring and personalization in treatment of breast cancer patients with metastatic bone lesions. Eureka: HS 2022. [DOI: 10.21303/2504-5679.2022.002270] [Reference Citation Analysis]
11 Aristei C, Machiels M, Royo LT, Prat MA. Oligometastatic and Oligoprogression Disease. Breast Cancer Radiation Therapy 2022. [DOI: 10.1007/978-3-030-91170-6_50] [Reference Citation Analysis]
12 Lévy A, Darréon J, Mornex F, Giraud P, Thureau S. Lung metastases radiation therapy. Cancer Radiother 2021:S1278-3218(21)00200-6. [PMID: 34953714 DOI: 10.1016/j.canrad.2021.08.011] [Reference Citation Analysis]
13 Kassar S, Samaha R, Aoun R, Khoury M, Kattan J. The concept of oligometastatic disease in gastric cancer: reality or fiction? Future Oncol 2022;18:135-8. [PMID: 34889659 DOI: 10.2217/fon-2021-1315] [Reference Citation Analysis]
14 Faivre-finn C, Venissac N, Besse B, Dansin E, Moro-sibolot D. Prise en charge des cancers bronchiques non à petites cellules oligométastatiques. Revue des Maladies Respiratoires Actualités 2021;13:2S109-2S120. [DOI: 10.1016/s1877-1203(21)00104-x] [Reference Citation Analysis]
15 Berzenji L, Debaenst S, Hendriks JMH, Yogeswaran SK, Lauwers P, Van Schil PE. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review. Transl Lung Cancer Res 2021;10:3409-19. [DOI: 10.21037/tlcr-21-58] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Mentink JF, Paats MS, Dumoulin DW, Cornelissen R, Elbers JBW, Maat APWM, von der Thüsen JH, Dingemans AC. Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review. Transl Lung Cancer Res 2021;10:3329-38. [PMID: 34430370 DOI: 10.21037/tlcr-21-265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Gobbini E, Bertolaccini L, Giaj-Levra N, Menis J, Giaj-Levra M. Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis. Transl Lung Cancer Res 2021;10:3339-50. [PMID: 34430371 DOI: 10.21037/tlcr-20-982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Herrera-caceres JO, Gleave A, Lajkosz K, Goldberg H, Woon DT, Berjaoui MB, Qaoud Y, Wettstein MS, Ahmad AE, Hamilton R, Kulkari G, Fleshner N. Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials? Urologic Oncology: Seminars and Original Investigations 2021;39:431.e1-8. [DOI: 10.1016/j.urolonc.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lacaze JL, Aziza R, Chira C, De Maio E, Izar F, Jouve E, Massabeau C, Pradines A, Selmes G, Ung M, Zerdoud S, Dalenc F. Diagnosis, biology and epidemiology of oligometastatic breast cancer. Breast 2021;59:144-56. [PMID: 34252822 DOI: 10.1016/j.breast.2021.06.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pirasteh A, Lovrec P, Pedrosa I. Imaging and its Impact on Defining the Oligometastatic State. Semin Radiat Oncol 2021;31:186-99. [PMID: 34090645 DOI: 10.1016/j.semradonc.2021.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Levy A, Roux C, Mercier O, Issard J, Botticella A, Barlesi F, Le Péchoux C. [Radiotherapy for oligometastatic non-small cell lung cancer patients]. Cancer Radiother 2021:S1278-3218(21)00109-8. [PMID: 34175225 DOI: 10.1016/j.canrad.2021.06.011] [Reference Citation Analysis]
22 Teixeira Loiola de Alencar V, Guedes Camandaroba MP, Pirolli R, Fogassa CAZ, Cordeiro de Lima VC. Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study. J Thorac Oncol 2021;16:1379-91. [PMID: 33964398 DOI: 10.1016/j.jtho.2021.04.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
23 Foster CC, Pitroda SP, Weichselbaum RR. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J 2020;26:96-9. [PMID: 32205532 DOI: 10.1097/PPO.0000000000000434] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
24 Switlyk MD. Magnetic resonance imaging for assessing treatment response in bone marrow metastases. Acta Radiol 2021;62:483-99. [PMID: 31154803 DOI: 10.1177/0284185119851234] [Reference Citation Analysis]
25 Nieder C, Mehta MP, Guckenberger M, Gaspar LE, Rusthoven CG, Sahgal A, Grosu AL, De Ruysscher D. Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models? Radiother Oncol 2021;159:17-20. [PMID: 33675870 DOI: 10.1016/j.radonc.2021.02.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Bongiovanni A, Foca F, Fantini M, Forcignanò MR, Artioli F, Berardi R, Campadelli E, Procopio G, Silvestris F, Riva N, Gurrieri L, Debonis SA, Di Menna G, Fausti V, Recine F, Vespignani R, Ibrahim T. First prospective data on breast cancer patients from the multicentre italian bone metastasis database. Sci Rep 2021;11:4329. [PMID: 33619285 DOI: 10.1038/s41598-021-83749-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Yoshida S, Takahara T, Arita Y, Toda K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy. Int Urol Nephrol 2021;53:1119-25. [PMID: 33452956 DOI: 10.1007/s11255-020-02762-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Isaac A, Lecouvet F, Dalili D, Fayad L, Pasoglou V, Papakonstantinou O, Ahlawat S, Messiou C, Weber MA, Padhani AR. Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging. Semin Musculoskelet Radiol 2020;24:726-50. [PMID: 33307587 DOI: 10.1055/s-0040-1719018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Dansin E, Le Tinier F, Brouchet L, Desmet A, Massabeau C, Van Houtte P, Khalifa J. Prise en charge des cancers bronchiques non à petites cellules oligométastatiques. Revue des Maladies Respiratoires Actualités 2020;12:2S94-2S103. [DOI: 10.1016/s1877-1203(20)30090-2] [Reference Citation Analysis]
30 Berghmans T, Lievens Y, Aapro M, Baird AM, Beishon M, Calabrese F, Dégi C, Delgado Bolton RC, Gaga M, Lövey J, Luciani A, Pereira P, Prosch H, Saar M, Shackcloth M, Tabak-Houwaard G, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer. Lung Cancer 2020;150:221-39. [PMID: 33227525 DOI: 10.1016/j.lungcan.2020.08.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
31 Tan B, Huang L, Wu Y, Liao J. Advances and trends of hydrogel therapy platform in localized tumor treatment: A review. J Biomed Mater Res A 2021;109:404-25. [PMID: 32681742 DOI: 10.1002/jbm.a.37062] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
32 Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward WA. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology 2020;148:157-66. [DOI: 10.1016/j.radonc.2020.04.003] [Cited by in Crossref: 162] [Cited by in F6Publishing: 182] [Article Influence: 81.0] [Reference Citation Analysis]
33 Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020;21:e18-28. [PMID: 31908301 DOI: 10.1016/S1470-2045(19)30718-1] [Cited by in Crossref: 310] [Cited by in F6Publishing: 354] [Article Influence: 155.0] [Reference Citation Analysis]
34 Chaw CL, deSouza NM, Khoo V, Suh YE, van As N. Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer. Clin Oncol (R Coll Radiol) 2020;32:509-17. [PMID: 32423621 DOI: 10.1016/j.clon.2020.03.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Aluwini SS, Mehra N, Lolkema MP, Oprea-lager DE, Yakar D, Stoevelaar H, van der Poel H, Busstra M, de Jong I, de Reijke T, de Vries K, Heijmink S, Jenster G, Klaver S, Kneppers J, Lavalaye J, Leyten G, Moonen L, Nagaraj J, Noordzij W, Osanto S, Oving I, Schaake E, Scheenen T, Schoots I, Sedelaar M, Somford D, van den Berkmortel F, van der Hulle T, van der Voort van Zyp J, van Leeuwen P, van Moorselaar J, van Oort I, Vogel W, Westgeest H. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. European Urology Oncology 2020;3:231-8. [DOI: 10.1016/j.euo.2019.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
36 Jin P, Ji X, Tian Y. Surgical management of oligometastatic disease in gastric cancer. Clin Res Hepatol Gastroenterol 2020;44:638-45. [PMID: 32147440 DOI: 10.1016/j.clinre.2020.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, Park K, Soo RA, Chang JWC, Alip A, Peters S, Douillard JY. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:171-210. [PMID: 30596843 DOI: 10.1093/annonc/mdy554] [Cited by in Crossref: 134] [Cited by in F6Publishing: 152] [Article Influence: 67.0] [Reference Citation Analysis]
38 Cho CJ, Vellayappan BA, Dunne EM, Siva S, Liu M, Louie AV, Hanna GG, Lo SS. What is synchronous oligometastatic non-small cell lung cancer? J Thorac Dis 2019;11:5666-9. [PMID: 32030296 DOI: 10.21037/jtd.2019.12.44] [Reference Citation Analysis]
39 Nieder C, Mannsåker B, Yobuta R. Late Brain Oligometastases Diagnosed at Least 36 Months after Cancer Detection are Associated with Favorable Survival Outcome. Cureus 2020;12:e6553. [PMID: 32042526 DOI: 10.7759/cureus.6553] [Reference Citation Analysis]
40 Hendriks LE, Dooms C, Berghmans T, Novello S, Levy A, De Ruysscher D, Hasan B, Giaj Levra M, Giaj Levra N, Besse B, Vansteenkiste J, Dingemans AC. Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. European Journal of Cancer 2019;123:28-35. [DOI: 10.1016/j.ejca.2019.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
41 Giaj-Levra N, Giaj Levra M, Berghmans T, Novello S, Hendriks LE, Levy A, Besse B, Dingemans AC. Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter? Lung Cancer 2020;139:216-8. [PMID: 31761473 DOI: 10.1016/j.lungcan.2019.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Levy A, Hendriks LE, Berghmans T, Faivre-finn C, Giajlevra M, Giajlevra N, Hasan B, Pochesci A, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'brien M, Reck M, Besse B, Novello S, Dingemans AC. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. European Journal of Cancer 2019;122:109-14. [DOI: 10.1016/j.ejca.2019.09.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
43 Fabian A, Pyschny F, Krug D. [Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study]. Strahlenther Onkol 2019;195:1113-5. [PMID: 31637448 DOI: 10.1007/s00066-019-01528-4] [Reference Citation Analysis]
44 Khalifa J, Brouchet L, Desmet A, Massabeau C, Van Houtte P. Les cancers bronchiques non à petites cellules oligométastatiques: définition et prise en charge. Revue des Maladies Respiratoires Actualités 2019;11:290-297. [DOI: 10.1016/s1877-1203(19)30099-0] [Reference Citation Analysis]
45 Confavreux CB, Pialat J, Bellière A, Brevet M, Decroisette C, Tescaru A, Wegrzyn J, Barrey C, Mornex F, Souquet P, Girard N. Métastases osseuses du cancer du poumon : un paradigme de la prise en charge pluridisciplinaire onco-rhumatologique. Revue du Rhumatisme 2019;86:453-463. [DOI: 10.1016/j.rhum.2019.06.004] [Reference Citation Analysis]
46 Moul JW. Yes or no to local therapy for oligometastatic prostate cancer? Nat Rev Urol 2018;15:399-400. [PMID: 29795250 DOI: 10.1038/s41585-018-0028-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Vu E, Guckenberger M. Paradigmenwechsel für stereotaktische Strahlentherapie bei Oligometastasierung. Onkologe 2019;25:38-46. [DOI: 10.1007/s00761-019-0617-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Wenz F, Witzel I, Wöckel A. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019;14:224-45. [PMID: 31558897 DOI: 10.1159/000501000] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 16.7] [Reference Citation Analysis]
49 Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019;14:2109-2119. [PMID: 31398540 DOI: 10.1016/j.jtho.2019.07.025] [Cited by in Crossref: 95] [Cited by in F6Publishing: 122] [Article Influence: 31.7] [Reference Citation Analysis]
50 Giaj-Levra N, Giaj-Levra M, Durieux V, Novello S, Besse B, Hasan B, Hendriks LE, Levy A, Dingemans AC, Berghmans T; European Organization for Research and Treatment of Cancer-Lung Cancer Group. Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review. J Thorac Oncol 2019;14:2053-61. [PMID: 31195177 DOI: 10.1016/j.jtho.2019.05.037] [Cited by in Crossref: 28] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
51 Nieder C, Dalhaug A, Pawinski A. Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer. In Vivo 2019;33:465-8. [PMID: 30804126 DOI: 10.21873/invivo.11495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Lee K, Park HY, Kim KW, Lee AJ, Yoon MA, Chae EJ, Lee JH, Chung HW. Advances in whole body MRI for musculoskeletal imaging: Diffusion-weighted imaging. J Clin Orthop Trauma 2019;10:680-6. [PMID: 31316239 DOI: 10.1016/j.jcot.2019.05.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
53 Pitroda SP, Weichselbaum RR. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol 2019;16:581-8. [DOI: 10.1038/s41571-019-0220-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 13.0] [Reference Citation Analysis]
54 Nieder C, Dalhaug A, Pawinski A. Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement. In Vivo 2019;33:229-32. [PMID: 30587628 DOI: 10.21873/invivo.11464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
55 Foster CC, Pitroda SP, Weichselbaum RR. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol 2019;37:1270-6. [PMID: 30939093 DOI: 10.1200/JCO.18.02021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
56 Gustin P, Botticella A, Tselikas L, Mercier O, Le Péchoux C, Levy A. Prise en charge thérapeutique des cancers bronchiques non à petites cellules oligoprogressifs. Revue des Maladies Respiratoires 2019;36:519-26. [DOI: 10.1016/j.rmr.2018.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Hendriks LEL, Dingemans AC. Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer? Lung Cancer 2019;129:95-7. [PMID: 30738574 DOI: 10.1016/j.lungcan.2019.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 De Visschere PJ, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, Maurer T, Hadaschik BA, Lecouvet FE, Giannarini G, Fanti S. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. European Urology Oncology 2019;2:47-76. [DOI: 10.1016/j.euo.2018.09.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 31.7] [Reference Citation Analysis]
59 Larbi A, Omoumi P, Pasoglou V, Michoux N, Triqueneaux P, Tombal B, Cyteval C, Lecouvet FE. Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI. Diagn Interv Imaging 2019;100:295-302. [PMID: 30704946 DOI: 10.1016/j.diii.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
60 Nicolotti DG, Finessi M, Guarneri A, Pilati E, Giunta F, Deandreis D. Impact of functional imaging in prostate cancer: a clinical point of view. Q J Nucl Med Mol Imaging 2019;63:1-6. [PMID: 30644307 DOI: 10.23736/S1824-4785.19.03160-1] [Reference Citation Analysis]
61 Li H, Wang G, Zhang H, Song X, Cao J, Zhang X, Xue R, Wang W, Jia S, Li Z. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations. Genes Immun 2019;20:455-61. [DOI: 10.1038/s41435-018-0050-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
62 Loriot Y, Supiot S, Beauval J, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit M, Borchiellini D. Management of non-metastatic castrate-resistant prostate cancer: A systematic review. Cancer Treatment Reviews 2018;70:223-31. [DOI: 10.1016/j.ctrv.2018.09.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
63 deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. Int J Cancer 2019;144:422-30. [PMID: 30098215 DOI: 10.1002/ijc.31793] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
64 Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-finn C, Mok T, Reck M, Van Schil P, Hellmann M, Peters S. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018;29:iv192-237. [DOI: 10.1093/annonc/mdy275] [Cited by in Crossref: 985] [Cited by in F6Publishing: 1118] [Article Influence: 246.3] [Reference Citation Analysis]
65 Lecouvet FE, Oprea-lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, Kramer G, Lievens Y, Lopci E, Pasquier D, Petersen LJ, Talbot J, Zacho H, Tombal B, deSouza NM. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. The Lancet Oncology 2018;19:e534-45. [DOI: 10.1016/s1470-2045(18)30571-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 80] [Article Influence: 17.5] [Reference Citation Analysis]
66 Desmet A, Van Schil P, Van Houtte P. Quelles stratégies thérapeutiques pour les CBNPC oligo-métastatiques ? Revue des Maladies Respiratoires Actualités 2018;10:326-331. [DOI: 10.1016/s1877-1203(18)30028-4] [Reference Citation Analysis]
67 Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer A, Ost P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere PJL, Tsaur I; EAU-YAU Prostate Cancer Working Party. Imaging modalities in synchronous oligometastatic prostate cancer. World J Urol 2019;37:2573-83. [PMID: 30069582 DOI: 10.1007/s00345-018-2416-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
68 Jadvar H. Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology. J Nucl Med 2018;59:1338-9. [PMID: 30030344 DOI: 10.2967/jnumed.118.213470] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
69 Beckert S, Königsrainer A. Oligometastasierung beim Magen- und Ösophaguskarzinom: Aktuelle Studienlage und chirurgische Konzepte. Chirurg 2018;89:505-9. [DOI: 10.1007/s00104-018-0645-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
70 Ding J, Xu Z, Zhang Y, Tan C, Hu W, Wang M, Xu Y, Tang J. Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis. Exp Cell Res 2018;369:129-38. [PMID: 29778754 DOI: 10.1016/j.yexcr.2018.05.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
71 Confavreux CB, Pialat JB, Bellière A, Brevet M, Decroisette C, Tescaru A, Wegrzyn J, Barrey C, Mornex F, Souquet PJ, Girard N. Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management. Joint Bone Spine 2019;86:185-94. [PMID: 29631067 DOI: 10.1016/j.jbspin.2018.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
72 Tombal B. Radiopharmaceuticals for the Detection of Recurrent Prostate Cancer. European Oncology & Haematology 2018;14:16. [DOI: 10.17925/eoh.2018.14.1.16] [Reference Citation Analysis]